Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sovaldi NDA Review Marred By Manufacturing Compliance Issues

This article was originally published in The Gold Sheet

Executive Summary

Faced with the prospects of FDA non-approval of its priority review hepatitis C drug sofosbuvir, Gilead withdrew a foreign API manufacturer and one of its own testing facilities from the NDA late in the review process due to GMP violations and data integrity concerns. This case study shows how manufacturing problems can threaten to derail an otherwise stellar application with strong efficacy and safety data.

Advertisement

Related Content

Top Stories of 2014
How Sovaldi Won A Broad Label: Emerging Data Swayed Reluctant FDA
“Breakthrough Therapy” Development Speed May Be Tempered By Manufacturing Hurdles
FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS000832

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel